ClinicalTrials.gg

BioNTech SE clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 124 studies whose lead sponsor is BioNTech SE or one of 6 companies grouped under it. 33 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 17, 2026.

Our grouping of 8 registry names, not the registry’s. See them and correct one ↓

Compare BioNTech with Merck and Hoffmann-La Roche →

Pipeline: 23 programs

Each counted once: 23 with a study BioNTech SE leads registered in the last two years.

  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4 (approved, new studies)

The 3 phase-3 programs — sign in to see them, free: with every program, filter by condition or phase and sort by first study or primary completion.

“Registry” is the highest phase of BioNTech SE’s own registered studies; BioNTech SE’s own pipeline document is not read yet. “Primary completion” is the earliest date still ahead among its live studies when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced. Programs are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.

Licenses and deals

One of BioNTech’s programs has a dated deal behind it: 1 developed with a partner. Each from the companies’ own releases and filings, linked; the registry does not record them.

Developed with a partner 1

  • pumitamig — developed with Bristol Myers Squibb, worldwide, profits and losses shared equally.Announced Jun 2, 2025 · Source: BioNTech, Jun 2, 2025

What it is testing

The drugs BioNTech SE’s studies test, most open studies first — 18 drugs with a page of their own. Each count opens the studies in search.

Open now Not open: under way, finished or stopped

Show 8 more

Coming up

11 of BioNTech SE’s studies under way reach primary completion within a year, 3 of them phase 3. The dates are the sponsor’s own estimates, which often move.

Phase 3 Other phases

  1. 2N’26
  2. D
  3. 1J’27
  4. F
  5. M
  6. 1A
  7. 2M
  8. 2J
  9. 1J
  10. 1A
  11. S
  12. O
  13. 1N

All 11

Show 6 more

Add all 11 to your calendar (.ics) → With an account.

All 124 at a glance

Where each study is in its life, its phase and its countries. Each count opens them in search.

  • Open now3327%Recruiting 29 · Not yet recruiting 4
  • Under way, not recruiting1512%
  • Completed5544%
  • Stopped early1915%Terminated 15 · Withdrawn 4
  • Status unknown or other22%

Phase

  • Phase 169
  • Phase 262
  • Phase 327
  • Phase 42

Where

  • United States63
  • Germany43
  • China31
  • Spain27
  • United Kingdom25
  • Australia22

Over the years

  1. 09
  2. 10
  3. 11
  4. 12
  5. 13
  6. 14
  7. 15
  8. 16
  9. 17
  10. 18
  11. 19
  12. 20
  13. 21
  14. 22
  15. 23
  16. 24
  17. 2225
  18. 1026

By the year each study started. 2026 so far in the lighter column.

Registry sponsor names on this page

Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.

Tell us about a missing company
No account needed. Please leave out personal details.

Each name exactly as ClinicalTrials.gov lists it, and how it relates to BioNTech SE.

  • BioNTech SE
    Same company
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    76 studies
  • Biotheus Inc.
    Acquired — became part of BioNTech SE, Feb 3, 2025 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    18 studies →
  • CureVac
    Acquired — became part of BioNTech SE, Dec 3, 2025 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    18 studies →
  • BioNTech US Inc.
    Same company
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    4 studies
  • BioNTech Research & Development, Inc.
    Subsidiary
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    3 studies →
  • BioNTech Diagnostics GmbH
    Subsidiary
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    2 studies →
  • BioNTech RNA Pharmaceuticals GmbH
    Subsidiary
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    2 studies →
  • BioNTech Cell & Gene Therapies GmbH
    Subsidiary
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    1 study →

Focus areas

Conditions BioNTech SE leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.

Studies

Recruiting first, then most recently updated. Showing 50 of 124. Browse all 124 →